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Aims. To assess the association of blood oxygen-transport capacity variables with the prevalence of diabetic retinopathy (DR),
retinal ischemia, and macular oedema in patients with type 2 diabetes mellitus (T2DM). Methods. Cross-sectional, case-control
study (𝑁 = 312) with T2DM: 153 individuals with DR and 159 individuals with no DR. Participants were classified according to the
severity of DR and the presence of retinal ischemia or macular oedema. Hematological variables were collected by standardized
methods.Three logisticmodels were adjusted to ascertain the association between hematologic variables with the severity ofDR and
the presence of retinal ischemia or macular oedema. Results. Individuals with severe DR showed significantly lower hemoglobin,
hematocrit, and erythrocyte levels compared with those with mild disease and in individuals with retinal ischemia and macular
oedema compared with those without these disorders. Hemoglobin was the only factor that showed a significant inverse association
with the severity of DR [beta-coefficient = −0.52, 𝑃 value = 0.003] and retinal ischemia [beta-coefficient = −0.49, 𝑃 value = 0.001].
Lower erythrocyte level showed a marginally significant association with macular oedema [beta-coefficient = −0.86, 𝑃 value =
0.055].Conclusions. In patients withDR, low blood oxygen-transport capacity was associatedwithmore severeDR and the presence
of retinal ischemia. Low hemoglobin levels may have a key role in the development and progression of DR.
1. Introduction
Type 2 diabetes mellitus (DM) is a common disease with
a prevalence and incidence that have increased in recent
decades.The estimated increase in the total number of people
with diabetes is from 366 million in 2011 to 552 million
in 2030 [1]. Diabetic retinopathy (DR), including diabetic
maculopathy, is a microvascular complication of DM and the
leading cause of visual disability in adults of working age in
developed countries. Its prevalence increases with age and
the duration of diabetes. It is estimated that after 20 years of
having diabetes, more than 20% of type 2 diabetic patients
will have some degree of DR [2].
The initial changes in DR affect the microcirculation of
the retina. The lesions observed in these patients are sec-
ondary to this microangiopathy and result in increased vas-
cular permeability in the form of edema and retinal vascular
occlusive disease. The retina is among the most active
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metabolic tissues of the human body and is highly sensitive
to reductions in oxygen tension [3]. Some studies have
suggested that hypoxia is a stimulus for the production of
intraocular and systemic erythropoietin (EPO) [3–5] and for
vascular endothelial growth factor (VEGF). Both EPO and
VEGF are neuroprotective factors that possess likely angio-
genic potential, leading to an increase in the proliferation
of new retinal vessels and thus inducing the development of
proliferative retinopathy.
Macular edema (ME) may appear at any stage of DR and
is the main cause of central visual loss in diabetic patients.
It is defined as an increase in tissue fluid, which causes a
thickening of the retina and secondarily causes structural and
functional alterations with important clinical consequences.
According to data from the Wisconsin Epidemiologic Study
of Diabetic Retinopathy (WESDR) [6], after 15 years of
known diabetes, the prevalence of diabetic macular edema
is approximately 25% and 14% in patients with type 2 DM
treated with and without insulin, respectively.
Despite not fully understanding the pathogenic mecha-
nisms of DR andME, there are a large number of multicenter
studies that have assessed the risk factors involved in DR
and ME development and progression [7–11]. The duration
of diabetes, glycemic control, and the systolic blood pressure
are the most accepted and widely documented risk factors.
Several authors have also suggested that hemoglobin,
hematocrit, and blood viscosity levels can contribute to the
development and progression of DR [12–16]. Low hemo-
globin was an independent baseline risk factor for the
development of proliferative diabetic retinopathy (PDR) and
severe visual loss in the Early TreatmentDiabetic Retinopathy
Study (ETDRS) report [12]. Other studies have corroborated
this finding and found an improvement in DR status follow-
ing a correction of the anemia [13, 17–19]. A prospective study
published by Qiao et al. in 1997 showed an inverse indepen-
dent relationship between hemoglobin concentrations and
the development of DR, particularly severe forms of DR [13].
Similarly, we sought to assess whether a lower blood
oxygen-transport capacity may be associated with the pres-
ence and severity of retinal disease in type 2 diabetes. To
accomplish this, we determined the potential association of
hematological factors, particularly the hemoglobin concen-
tration, with the presence and severity of diabetic retinopathy,
retinal ischemia, and macular edema in patients with type 2
diabetes.
2. Methods
2.1. Study Population. This was a prospective, observational,
exploratory study of cases (𝑛 = 153) and controls (𝑛 =
159). It included subjects with type 2 DM with retinopathy
(cases) and without DR (controls). This study was initially
designed to evaluate the presence of subclinical micro- and
macrovascular disease associated with diabetic retinopathy.
In a recent publication, we described the increased fre-
quency of subclinical atherosclerosis associated with diabetic
retinopathy [20]. We took advantage of this study in which
312 type 2 diabetic patients aged 40–75 years without known
clinical cardiovascular disease or renal failure (glomerular
filtration rate < 60mL/min) were included. The presence or
absence of diabetic retinopathy was used for the allocation of
the study groups by study design. To avoid including patients
with additional microangiopathic burden, patients without
retinopathy also had a current and previous normal urinary
albumin: creatinine ratio (<30mg/g). In the subgroup of
diabetic patients with retinopathy, macroalbuminuria (urine
albumin: creatinine ratio > 299mg/g) was an additional
exclusion criterion. We selected patients of several different
ages to achieve a similar age distribution in the groups.
All of the diabetic patients were recruited from the
outpatient clinic at our center. Potential candidates were
identified from the screening and treatment diabetic eye
disease program of our center. The clinical characterization
of these patients has been recently described [20]. None
of the patients included had a hemoglobinopathy. From
an ophthalmological point of view, we also considered the
following as exclusion criteria: refractive errors (spheric
equivalent) > ±3.00 diopters; average opacity that made
data analysis difficult; presence of other concomitant retinal
pathology; surgery during the previous year; inflammatory
conditions in the anterior or posterior segment; glaucoma
treatment; and laser photocoagulation within the previous
6 months. The local ethics committee approved the study,
according to the Helsinki Declaration. All patients signed an
informed consent form.
2.2. Definition of Variables. All patients underwent a clinical
evaluation that included age, sex, ethnicity, antidiabetic treat-
ment, treatment for dyslipidemia and hypertension, use of
antiplatelet drugs, systolic and diastolic blood pressure, body
mass index, hemoglobin HbA1c, lipid profile, creatinine, and
urinary albumin/creatinine ratio. Data on these variables
from the study subjects have been already published [20]
and are used here for the purpose of analysis of the present
study outcomes. The methodology used to assess the clinical
variables is described in detail elsewhere [20]. For the specific
purpose of the current study, a blood count that included
hemoglobin, hematocrit, and erythrocytes was conducted
with the model TOASYSMEX XN-20 device (Roche, Japan).
2.3. Ophthalmic Examination. Patients underwent a com-
plete eye examination to assess the presence or absence of
diabetic retinopathy, clinically significant macular edema,
and retinal ischemia.
According to a modified version of the American Acad-
emy Ophthalmology classification [21], the patients were
classified according to the presence or absence of diabetic
retinopathy (DR) and its severity: absence ofDR (NDR),mild
nonproliferative DR (NPDR), moderate to severe NPDR, and
proliferative diabetic retinopathy (PDR). For the statistical
analyses, we categorized the presence of diabetic retinopathy
into 2 groups: group 1, mild DR, and group 2, DR > mild
(including moderate DR, severe DR, or PDR).
Clinically significantmacular edema (CSME)was defined
according to the Early Treatment Diabetic Retinopathy Study
(ETDRS) classification protocol: the presence of retinal
thickening at or within 500𝜇m of the center of the macula,
hard exudates at or within 500𝜇mof the center of the macula
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associated with thickening of the adjacent retina, and/or
zones of retinal thickening 1 disc area in size and at least
partially within a 1 disc diameter of the center [22].
The ophthalmologic examination included an automatic
refraction (MRK-3100P, Huvitz), collection of the best cor-
rected visual acuity, measurement of intraocular pressure
(applanation tonometer measured by model AT 900, Haag-
Streit), exploration with slit-lamp of the anterior segment,
and pupil dilation with 1% tropicamide (Superfield NC and
90D and +78D Volk lens).
Visual acuity in each eye was measured on the Snellen
chart and recorded as a decimal value with the best refraction
for distance, and the data were applied to the logMAR
(logarithm of the minimum angle of resolution) ETDRS
chart. All data handling on visual acuity is expressed in
logMAR format.
The fundi of all the patients were photographed using a
45∘ field stereoscopic digital fundus camera (TOPCON TRC:
50IX, retinal camera), centered first from the temporal to the
macula and second from the nasal to the papilla [23]. For
those who showed evidence of any retinopathy, additional 30∘
seven-field stereo digital pairs were taken.
The patients with identified diabetic retinopathy under-
went a fluorescein angiography. The fluorescein angiography
was performed according to a standard procedure and was
used to assess the foveal avascular zone (FAZ) and peripheral
retinal ischemia according to the ETDRS standards [24]. Two
30∘ fields extending along the horizontal meridian from 25∘
nasal to the disc to 20∘ temporal to the macula and four
45∘ peripheric fields were selected for further analysis. The
presence of retinal ischemia was assessed by the capillary loss
both in the peripheral areas and in the central subfield. The
patients were classified into two groups: group 1, which had
an absence of retinal ischemia, and group 2, in whom retinal
ischemia was present (macular or peripheral to any degree).
An optical coherence tomography (OCT) was carried out
in all the patients to evaluate themacular area.TheOCT used
was the Stratus Optical Tomography 3 (Carl Zeiss Meditec,
Dublin, CA, USA). The analysis of results was carried out
using the Fast Macular Thickness Map.
2.4. Statistical Review. The continuous variables are pre-
sented as the mean and interquartile range, and the cat-
egorical variables are presented as proportions. We used
the Mann-Whitney 𝑈 and Chi-square tests to compare the
means and the proportions of the risk factors for diabetic
retinopathy and hematological factors (hemoglobin (Hb),
hematocrit (Htc), erythrocytes, mean corpuscular volume
(MCV), mean corpuscular hemoglobin (MCH), and mean
corpuscular hemoglobin concentration (MCHC)), according
to the presence of DR, the presence of mild DR versus
DR >mild (moderate/severe/proliferative), the presence of
retinal ischemia versus absence of retinal ischemia, and the
presence of EMCS versus absence of EMCS.
Three logistic regression models for each of the vari-
ables considered were used (mild DR versus DR > mild,
retinal ischemia, and EMCS). The variables that showed a
statistically significant association in the bivariate analysis
with each of the variables of interest were used as potential
confounders. The adjustment of the logistic regression mod-
els followed the stepwise procedure, and those that showed
a significant association with the variables of interest were
adjusted. The saturated models mild DR versus DR > mild
and retinal ischemia were adjusted by hemoglobin, sex, and
the interaction sex-hemoglobin. Finally, the EMCS saturated
model was adjusted by erythrocytes, sex, and interaction sex-
erythrocytes. We tested whether there was an interaction
between hemoglobin and sex for each of the variables of
interest (mild DR versus DR > mild, the retinal ischemia,
and the EMCS). A univariate logistic regression model
was adjusted, in which the association was estimated and
stratified by sex of the DR patient with hemoglobin for the
variables that exhibited a significant interaction.
3. Results
3.1. Characteristics of Studied Subjects. As already explained
above, the general clinical characteristics of the study groups
have already been published [20]. The assessment of the
characteristics of the study groups showed that, compared
with the subjects without retinopathy, the diabetic subjects
with retinopathy had a longer diabetes duration, higher
HbA1c concentration, andhigher prevalence of hypertension,
systolic blood pressure, and urinary albumin excretion. The
patients with retinopathy had also greater waist circumfer-
ence and HDL-c. Additionally, they were more likely to be on
insulin treatment and on antiplatelet drugs.
There were no differences in any of the hematological
variables between patients with and those without retinopa-
thy (Table 1). Additionally, no significant differences were
observed between the concentrations of iron and ferritin
(Table 1).
The distribution of retinopathy grades was as follows: 60
patients had mild NPDR (39.2%) and 93 patients NPDR >
mild (57 moderate NPDR (37.3%), 29 severe NPDR (18.9%),
and 7 PDR (4.6%)). The patients with retinopathy were
slightly older.The proportion ofmale/female subjects was not
different between the groups.
3.2. Relationship among Variables of Interest, General Factors,
and Hematological Values in Patients with Diabetic Retinopa-
thy. We next investigated the potential association of the
hematological variables with the severity of retinopathy and
the presence of retinal ischemia and macular edema in
patients with DR.
The patients with a degree of diabetic retinopathy greater
than mild (moderate/severe/proliferative) presented with
higher glycated hemoglobin, systolic blood pressure, triglyc-
erides, and urinary albumin excretion and were more likely
on insulin treatment. Hb, Htc, and erythrocytes were signif-
icantly decreased with the increasing severity of DR. Table 2
shows the variables that were statistically significant in the
comparison between the groups.
Among the 153 study patients with DR, 58 had some
degree of retinal ischemia (macular and/or peripheral).These
patients were older, had a longer diabetes duration, were
more likely to be on insulin treatment, and had a higher
prevalence of microalbuminuria. The patients in the group
4 Journal of Diabetes Research
Table 1: Hematological variables of the study groups according to presence or absence of diabetic retinopathy (DR).
Without DR
(𝑛 = 159)
With DR
(𝑛 = 153) 𝑃 value
Leukocytes (×109/L) 6670 (5600–7730) 6795 (5685–8035) 0.3765
Hemoglobin (gr/dL) 13.8 (13–14.6) 13.6 (12.8–14.8) 0.5435
Erythrocytes (×1012/L) 4.6 [4.4–5.0] 4.6 [4.4–4.9] 0.9407
Hematocrit (%) 41.10 [39–43.9] 40.95 [38.8–43.25] 0.7114
MCV (fL) 87.8 [85.1–90.5] 87.6 [85.0–90.1] 0.6169
MCH (pg) 29.4 [28.4–30.6] 29.3 [28.0–30.7] 0.4814
MCHC (g/dL) 33.5 [32.8–34.1] 33.4 [32.7–34.3] 0.7543
Fe (𝜇g/dL) 78 (63–99) 74 (58–96) 0.2534
Ferritin (ng/mL) 131.2 (55.5–227.8) 98.5 (38–211.9) 0.0624
Data are presented as medians and interquartile ranges. BP: blood pressure, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, and
MCHC: mean corpuscular hemoglobin concentration.
Table 2: General and hematological variables that showed statistically significant differences in the comparison between groups according
to severity of retinopathy in the group of patients with diabetic retinopathy.
Mild diabetic retinopathy
(𝑛 = 60)
>mild diabetic retinopathy
(𝑛 = 93) 𝑃 value
Serum glucose (mg/dL) 150 [113–181] 175 [135–217] 0.012
Systolic BP (mmHg) 139 (125–147) 149 (135–164) 0.0008
Insulin treatment, 𝑛 (%) 2 (13.88%) 16 (10.45%) 0.0020
Triglycerides (mmol/L) 138 [88–177] 110 [81–153] 0.041
Urinary albumin: creatinine ratio, mg/g 8.21 [4.84–18.8] 18.7 [7.3–39.6] 0.003
Leukocytes (×109/L) 7.40 [6.11–8.39] 6.42 [5.54–7.84] 0.050
Hemoglobin (gr/dL) 14.0 [13.2–15.0] 13.4 [12.6–14.4] 0.005
Erythrocytes (×1012/L) 4.8 [4.6–5.0] 4.6 [4.4–4.9] 0.007
Hematocrit (%) 42.3 [40.0–43.8] 40.4 [38.4–42.1] 0.005
without retinal ischemia were more often smokers, but this
was not statistically significant (𝑃 = 0.0621). Hb, Htc, and
erythrocytes were significantly reduced in the group with
retinal ischemia compared with the group without retinal
ischemia (Table 3).
In patients with clinically significant macular edema
(𝑛 = 54), higher systolic blood pressure and urinary
albumin excretion were observed. The levels of Hb, Htc,
and erythrocytes were significantly reduced in this group
comparedwith the patients withoutmacular edema (Table 4).
3.3. Relation between DR, Retinal Ischemia, CSME, and
Hematological Variables in Patients with Diabetic Retinopathy.
The results of the multivariate models showed that lower
levels of hemoglobin were associated with the severity of DR
and the presence of retinal ischemia. In the case of macular
edema, the associationwith the lower number of erythrocytes
was significant. In addition, a significant interaction between
the level of hemoglobin and sex, depending on the degree of
diabetic retinopathy, was observed (Table 5).Themultivariate
analysis stratified by gender for the model of mild DR versus
>mild DR yielded a significant hemoglobin and sex interac-
tion, with higher levels of hemoglobin being against diabetic
retinopathy in women [odds ratio (confidence interval 95%)
= 0.374 (0.205–0.682); 𝑃: 0.001], whereas, in men, the odds
ratio of this association was not significant.
4. Discussion
The results of our study failed to demonstrate an independent
association between the concentration of Hb and the pres-
ence of DR. However, we found that lower Hb is associated
with severe forms of DR and with the presence, until now not
described, of retinal ischemia. We also demonstrated for the
first time an association between low levels of red blood cells
and the presence of EMCS.
Different factors have been described to be associated
with the development and severity of DR in patients with
type 2 DM [7–11]. These include the duration of DM, insulin
treatment, high blood pressure, higher serum lipids, and high
glycated hemoglobin urinary albumin excretion. Our study
coincides with those published earlier and yields the results
of a sample of patients without other advanced diabetic
complications.
Anemia is suggested as another long-term complication
of DM and, together with ischemia, has been associated
with the development and progression of both microvascu-
lar and macrovascular complications. Ischemia is a critical
component of DR, and it is potentially influenced by anemia,
Journal of Diabetes Research 5
Table 3: General and hematological variables that showed statistically significant differences in the comparison between groups according
to the presence or absence of retinal ischemia in the group of patients with diabetic retinopathy.
Absent retinal ischemia
(𝑛 = 95)
Present retinal ischemia
(𝑛 = 58) 𝑃 value
Urinary albumin: creatinine ratio, mg/g 9.4 [5.2–21.4] 25.0 [8.4–76.2] 0.002
Disease duration (yr) 10 (5–15) 16.5 (8–23) 0.0015
Insulin treatment, 𝑛 (%) 40 (42.1%) 43 (74%) 0.038
Smoking 7 (12.1%) 23 (24.5%) 0.0621
Hemoglobin (gr/dL) 14.0 [13.1–14.9] 13.1 [12.5–13.9] <0.001
Erythrocytes (×1012/L) 4.8 [4.5–5.0] 4.6 [4.3–4.9] 0.002
Hematocrit (%) 41.7 [39.9–43.8] 39.7 [36.6–41.4] <0.001
Table 4: General and hematological variables that showed statistically significant differences in the comparison between groups according
to the presence or absence of CSME in the group patients with diabetic retinopathy.
Diabetic retinopathy without
CSME
(𝑛 = 99)
Diabetic retinopathy with CSME
(𝑛 = 54) 𝑃 value
Urinary albumin: creatinine ratio, mg/g 9.2 [5.1–22.0] 23.3 [9.4–68.8] <0.001
Systolic BP (mmHg) 141 (129–154) 148 (135–165) 0.0337
Hemoglobin (gr/dL) 13.8 [13.0–14.9] 13.2 [12.6–14.1] 0.047
Erythrocytes (×1012/L) 4.7 [4.5–5.0] 4.6 [4.3–4.8] 0.019
Hematocrit (%) 41.3 [39.2–43.5] 40.3 [38.3–42.0] 0.047
themain indicator of the blood oxygen delivery capacity [25].
Previous studies have suggested that, compared with normal
red blood cells, the erythrocytes of diabetic patients have
decreased deformability and increased aggregation at the
capillary level [26–30].This condition couldmake themmore
fragile and susceptible to breakage, which would lower the
hemoglobin levels.This findingmay suggest that hypoxia that
occurs as a result of anemia acts as a stimulus for the release
of inflammatorymediators and vasoproliferative factors, such
as VEGF and EPO, that are capable of increasing vascular
permeability and contribute to the development of ME and
more severe forms ofDR.High intravitreal levels of EPOhave
been shown in cases of proliferative DR and in patients with
diabetic ME [3–5].
There are several studies showing the role of anemia as
an independent risk factor for diabetic retinopathy, partic-
ularly in population-based studies [12, 13, 15, 26]. Among
them, Davis et al. [12] demonstrated that, in ETDRS, low
hemoglobin and hematocrit levels were independent baseline
risk factors for the development of high-risk proliferative
diabetic retinopathy and severe vision loss over a 5-year
follow-up. Garc´ıa-Ramı´rez et al. [3] found that diabetic
patients with hemoglobin levels below 12mg/dL were two
times more likely to develop DR. A similar risk of anemia
with severe retinopathy was also reported in a case series
by Shorb [26]. Irace et al. [15] showed that the levels of
blood viscosity, Htc, and hemoglobin were lower in patients
with DR compared with subjects without retinopathy [15]. In
addition, the levels of these hematological variables decreased
as the degree of retinopathy increased. In that study, 190 type
2 diabetic patients both with and without DR were compared
with 95 controls without DM. Premenopausal women and
patients with renal failure were excluded. However, neither
retinal ischemia nor macular edema was considered.
Other studies in the literature consider anemia to be a
predictor of DR [11, 14, 17]. Rani et al. [17] showed that
type 2 diabetic patients with anemia were 1.80 times more
likely to develop diabetic retinopathy than were individuals
without anemia. In contrast to our study, this article did not
analyze a control group without retinopathy, nor was renal
function accounted for. Karoli et al. [11] did consider a study
population of type 2 diabetes with normoalbuminuria and
normal glomerular filtration and established that low Hb
levels are a risk factor for the development of DR. We did not
find an association between low levels of Hb and the presence
or absence of DR. This is most likely explained by the design
of our study and the number of patients in the control group.
Anemia and low hematocrit have been found to also be
associated with the presence of diabetic macular edema [31,
32]. In our study, we have corroborated these results, and we
demonstrated an independent association between low levels
of erythrocytes and the presence of EMCS.
There were several limitations in the present study that
should be noted here because they may affect the general-
ization of our findings. Because this was a cross-sectional
study, the results do not provide information on the potential
causation effect of hemoglobin. Prospective and larger studies
are required to overcome this limitation. Further, the results
of this study should be interpreted with caution because
it was not designed primarily to respond to these associ-
ations. The evaluation of the association between hemato-
logical parameters and the presence and severity of DR was
6 Journal of Diabetes Research
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a secondary objective. For this reason, though themajority of
the patients included in the study were postmenopausal, this
variable was not evaluated.
One of the strengths of this study is its case-control
design, which enabled us to assess whether there are differ-
ences between patients with and without DR. The specific
exclusion of other complications associated with diabetes,
such as nephropathy and cardiovascular disease, provides us
with a study population that is free of microvascular and
macrovascular disease, with the exception of the retinopathy.
This eliminates the influence of these factors, especially renal
insufficiency, as confounding variables and differentiates this
study from the majority of the previously published studies.
5. Conclusion
There is an association of low blood oxygen-transport capac-
ity, measured by hemoglobin concentration, and an increased
severity of DR and the presence of retinal ischemia. These
findings might have clinical implications, such as those
in attempt to better control hemoglobin concentrations in
diabetic patients, particularly in those with advanced forms
or DR ischemia. In patients with these conditions, it would be
advisable tomonitor and prevent anemia. Prospective studies
specifically designed to test these associations are needed to
confirm low values of hemoglobin as a risk factor for DR
and retinal ischemia also in patients with type 1 DM. Clinical
trials in patients with anemia are needed for the further
confirmation of these associations.
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